跳至主要内容
临床试验/JPRN-UMIN000025865
JPRN-UMIN000025865招募中未知

Effects of once-yearly injected zoledronic acid hydrate on bone mineral density in patients with primary osteoporosis after daily teriparatide treatment - Effects of zoledronate therapy in patients with primary osteoporosis after teriparatide treatment

Ainomemorial hospital0 个研究点目标入组 45 人开始时间: 2017年2月28日最近更新:
适应症

试验速览

阶段
未知
状态
招募中
发起方
入组人数
45

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
55years-old 至 ot applicable(—)
性别
Female

入选标准

  • 未提供

排除标准

  • 1)Anaphylaxis or any history of hypersensitivity to zoledronic acid and other kinds of bisphosnate 2)Serious renal dysfunction: creatinine clearance< 35ml/min 3) Serious heart disease, serious liver dysfunction, diabetes mellitus 4)Endocrine and metabolic disaease which may affect to the bone metabolism, and secondary osteoporosis(e.g. glucocorticoide-induced osteoporosis, rheumatoid arthiritis, immobilization osteoporosis) 5) Patients treated with medication which affect to the bone metabolism as follows, i)Glucocorticosteroids(more than 5mg for over 3 months) except inhaler or nasal drugs ii) Anticancer drugs 6) Patient of the hypocalcemia 7) A pregnant woman or the woman who might be pregnant 8)Patients who was diagnosed all of the L2, L3 and L4 vertebral fractures before zolendronate injection 9)Ptients who were jugged to be inadequate for this study by investigators

研究者

发起方
Ainomemorial hospital

相似试验